Jorgensen Nathan D.

SEC source: 0001104659-26-020179 · tm267337-2_4seq1.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 151,416

F1 · kind: Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 9, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 21, 2026. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 9, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 21, 2026. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.86, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-26-012669 · tm265871-1_4seq1.xml · derivative · entry 2

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,500

Underlying: Common Stock · 150,500 shares

Expires 2036-02-06

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 6, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-26-012669 · tm265871-1_4seq1.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 156,084

F1 · shares: Consists of shares of common stock issuable under an aggregate of 32,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 6, 2026. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-25-097522 · tm2528202d1_4seq1.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,834

F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter adopted by the reporting person on May 9, 2025 effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on October 3, 2025. The sales do not represent a discretionary trade by the reporting person.

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter adopted by the reporting person on May 9, 2025 effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on October 3, 2025. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.74 to $4.85, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-25-016510 · tm257355-1_4seq.xml · derivative · entry 2

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,000

Underlying: Common Stock · 103,000 shares

Expires 2035-02-21

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 21, 2025. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-25-016510 · tm257355-1_4seq.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,500

F1 · shares: Consists of shares of common stock issuable under an aggregate of 51,500 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 21, 2025. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-24-105438 · tm2425390-1_4seq1.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

F1 · shares: This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

F2 · shares: Consists of shares of common stock underlying a restricted stock unit ("RSU") award. Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is October 1, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting upon the one-year anniversary of such vesting commencement date and the remainder vesting in equal annual installments thereafter, subject to the Reporting Person's continued service as an employee.

SEC source: 0001104659-24-078547 · tm2419082-2_4seq1.xml · derivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-07-08

F1 · shares: This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4).

F2 · derivative.exercise_date: The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee.

SEC source: 0001415889-24-012459 · form4-05072024_040508.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 189,403

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-012157 · form4-05032024_040516.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,237

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-006594 · form4-03052024_040329.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 191,154

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-003036 · form4-02082024_100233.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 197,464

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001415889-24-002096 · form4-02012024_120227.xml · derivative · entry 2

Jorgensen Nathan D. · CIK 0001842523 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-01-28

F3 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001415889-24-002096 · form4-02012024_120227.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 198,449

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2024, subject to the Reporting Person's continued service as of each such date.

F2 · balance_after: Includes 2,802 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan.

SEC source: 0001209191-23-054696 · doc4.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,647

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001209191-23-048387 · doc4.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,481

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.

SEC source: 0001209191-23-045192 · doc4.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,791

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").

SEC source: 0001209191-23-028462 · doc4.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,625

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").

SEC source: 0001209191-23-014918 · doc4.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,459

F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs").

SEC source: 0001209191-23-007782 · doc4.xml · derivative · entry 2

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,000

Underlying: Common Stock · 91,000 shares

Expires 2033-02-05

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-23-007782 · doc4.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,769

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning February 6, 2023, subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-22-048724 · doc4.xml · derivative · entry 2

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,000

Underlying: Common Stock · 86,000 shares

Expires 2032-08-31

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 24 successive equal monthly installments beginning on October 1, 2022, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-22-048724 · doc4.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,269

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in four equal installments on each of March 1, 2023, September 1, 2023, March 1, 2024 and September 1, 2024, in each case, subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-22-006802 · doc4.xml · derivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2032-01-31

F1 · derivative.exercise_date: This option vests over four years in equal monthly installments beginning on February 1, 2022.

SEC source: 0001209191-21-008899 · doc4.xml · derivative · entry 2

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,534 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.

SEC source: 0001209191-21-008899 · doc4.xml · nonDerivative · entry 1

Jorgensen Nathan D. · CIK 0001842523 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,269

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 13.6 for-one basis, and had no expiration date.